ClinicalTrials.gg
CompletedNCT05884372ESCORTUpdated Nov 24, 2025

Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)

A Phase 4 interventional study of Eldecalcitol and Native Vitamin D in Osteoporosis in Postmenopausal Women, sponsored by Xi'an Honghui Hospital. Completed at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Xi'an Honghui Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Enrollment
37th of 57
100 · median 120
Started
2023
with 7 others
Phase 4
13 of 87
2 open now
Registered
51st of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 37th largest by enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2023, is one of 13 in phase 4, and was the 51st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

Primary objective:

To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.

Secondary objective:

To compare the efficacy of denosumab with eldecalcitol or native vitamin D treatment in postmenopausal women with osteoporosis on bone turnover markers, serum PTH, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.

03

Conditions studied

  • Osteoporosis in Postmenopausal Women

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. patients with osteoporosis, measured by dual energy X-ray absorptiometry (DXA), the T value of lumbar spine, femoral neck or total hip BMD is ≤-2.5, or with low mineral density (-2.5 \< T-score \< -1.0) plus a fragility fracture of the proximal humerus or distal forearm, or a history of vertebral compression fracture.
  • 2.Voluntarily participate in this study and sign the .

Exclusion criteria

Exclusion Criteria:

  • 1.Suffering from hyperthyroidism, Cushing's syndrome, hypogonadism, poorly controlled diabetes mellitus ( [HbA1c>9.0%]), or other diseases that may lead to secondary osteoporosis.
  • 2.Patients who have received denosumab therapy before screening: received oral bisphosphonate treatment more than 3 years or received bisphosphonate treatment within 6 months before screening, or received treatment with , vitamin K, active vitamin D compounds, selective estrogen receptor modulators, calcitonin, hormone replacement therapy, or teriparatide within the 8 weeks prior to study enrollment..
  • 3.Patients who at screening have urinary tract stones detected on B-mode ultrasonography or who have a prior history of urolithiasis.
  • 4.Corrected serum calcium value at screening exceeds 2.6mmol/L (10.4mg/dL) or serum calcium value is lower than 2.12mmol/L(8 mg/dL) or hypercalciuria (> 0.4 mg/dL GF), or chronic kidney disease ( \< 30 mL/min/1.73 m2).
  • 5.Patients with a history of malignant tumors.
  • 6.Patients judged by investigators to be unsuitable as subjects.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Denosumab+Eldecalcitol

    Denosumab (subcutaneous injection 60mg/6 months) combined with ELD (oral 0.75μg/day) for 12 months.

    Drug: Eldecalcitol · Drug: Denosumab

  • Active comparator
    Denosumab+Native Vitamin D+Calcium

    Denosumab (subcutaneous injection 60mg/6 months) combined with native vitamin D (oral 800IU/day) and Calcium (oral 600mg/day) for 12 months.

    Drug: Native Vitamin D · Drug: Denosumab · Drug: Calcium

Interventions

06

What researchers measure

Primary outcomes

  1. the percent change from baseline at month 12 in BMD at the lumbar spine L1-4.

    the percent change from baseline at month 12 in BMD at the lumbar spine L1-4.

    Time frame: 12 months

Secondary outcomes

  1. the percent change from baseline at month 6 in BMD at the lumbar spine L1-4.

    the percent change from baseline at month 6 in BMD at the lumbar spine L1-4.

    Time frame: 6 months

  2. the percent change from baseline at each visit in BMD at the femoral neck and total hip.

    the percent change from baseline at each visit in BMD at the femoral neck and total hip.

    Time frame: 12 months

  3. the percent change from baseline at each visit in serum CTX,P1NP,PTH.

    the percent change from baseline at each visit in serum CTX,P1NP,PTH.

    Time frame: 12 months

  4. the score change from baseline at month 6 and month 12 in quality of life by 16-item Assessment of Health-Related Quality of Life in Osteoporosis,(ECOS-16).

    the score change from baseline at month 6 and month 12 in quality of life by 16-item Assessment of Health-Related Quality of Life in Osteoporosis,(ECOS-16). The scale ranges from 16 to 80, with higher scores meaning higher risk.

    Time frame: 12 months

  5. Incidence rate of new vertebral fracture and new non-vertebral fracture in 1 year.

    Incidence rate of new vertebral fracture and new non-vertebral fracture in 1 year.

    Time frame: 12 months

Other outcomes

  1. the change from baseline at month 6 and month 12 in body balance ability by measuring One Leg Standing (OLS).

    the change from baseline at month 6 and month 12 in body balance ability by measuring One Leg Standing (OLS).

    Time frame: 12 months

  2. the change from baseline at month 6 and month 12 in limb skeletal muscle content by DXA.

    the change from baseline at month 6 and month 12 in limb skeletal muscle content by DXA.

    Time frame: 12 months

  3. the change from baseline at month 6 and month 12 in physical function by measuring 5 times chair stand.

    the change from baseline at month 6 and month 12 in physical function by measuring 5 times chair stand.

    Time frame: 12 months

  4. the change from baseline at month 6 and month 12 in muscle strength by measuring handgrip strength.

    the change from baseline at month 6 and month 12 in muscle strength by measuring grip strength.

    Time frame: 12 months

  5. the change from baseline at month 6 and month 12 in body balance ability by measuring 10 Meter Walk (10MW).

    the change from baseline at month 6 and month 12 in body balance ability by measuring 10 Meter Walk (10MW).

    Time frame: 12 months

  6. the change from baseline at month 6 and month 12 in body balance ability by measuring Timed Up and Go (TUG).

    the change from baseline at month 6 and month 12 in body balance ability by measuring Timed Up and Go (TUG).

    Time frame: 12 months

07

Study locations

1 site
  • Zeng,Yuhong
    Xi'an, China
08

References and documents

Publications

  • Zeng Y, Tang Q, Yang J, Li Q, Yang L, Zhang B, Yang M, Che M, Peng Y. Comparison of Efficacy and Safety of Denosumab with Eldecalcitol or Native Vitamin D in Postmenopausal Chinese Women with Osteoporosis (ESCORT): A Randomized Controlled Trial. J Clin Med. 2026 Jul 16;15(14):5570. doi: 10.3390/jcm15145570. PubMed 42513484 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2025, 22 months.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 22 months is below that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2023
First posted
Jun 1, 2023
StartActual
Aug 24, 2023
Primary completionActual
Jul 16, 2025
CompletionActual
Jul 16, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05884372
Lead sponsor
Xi'an Honghui Hospital
Collaborators
Chugai Pharma China Co., Ltd.
Responsible party
Yuhong Zeng (Chief Physician, Xi'an Honghui Hospital) — Principal investigator
First posted
Jun 1, 2023
Start date
Aug 24, 2023
Primary completion
Jul 16, 2025
Completion
Jul 16, 2025
Last update
Nov 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eldecalcitol

Start the discussion